HIV reservoir dynamics according to the timing of antiretroviral therapy initiation or modification - 01/05/26
, Christine Cheneau c, Jakub Kowalczyk d, Jean-Pierre Faller e, Martin Martinot f, Mahsa Mosheni-Zadeh f, Anne Fuchs c, David Rey c, Samira Fafi-Kremer a, bHighlights |
• | A successful dolutegravir-based regimen can reduce levels of total HIV DNA in viremic individuals, although the extent of this reduction varies. |
• | A successful dolutegravir-based regimen can reduce levels of residual immune activation in viremic individuals, although the extent of this reduction varies. |
• | A successful dolutegravir-based regimen, when used as a switching regimen, has no impact on HIV reservoir nor inflammation. |
Abstract |
Introduction |
HIV reservoir is the main barrier to HIV cure but its size dynamics on antiretroviral therapy (ART) in various clinical settings is poorly characterized.
Methods |
Responders to a dolutegravir-based regimen (DBR) enrolled in the DRONE study were analyzed for longitudinal total HIV DNA and immune activation biomarkers (sCD14, sCD163, IL-6, IP-10).
Results |
Overall, 169 participants were allocated to various groups: ART-naive acute infections (AI, n = 20) or chronic infections (CI, n = 21), and ART-treated individuals in virological success (VS, n = 116) or failure (VF, n = 12). HIV DNA significantly decreased at W48 of successful DBR in the AI (median: −1.3 log 10 copies/million PBMCs), CI (−0.6), and VF (−0.5) groups, but not in the VS group. Activation biomarkers decreased on DBR only for individuals with ongoing HIV replication at baseline.
Conclusion |
Successful DBR was associated with rapid HIV DNA decline in ART-naive and ART-failing individuals but not in the context of ART switch.
Le texte complet de cet article est disponible en PDF.Keywords : Integrase inhibitor, HIV reservoir, HIV DNA, Inflammation, Acute infection
Plan
Vol 56 - N° 3
Article 105264- avril 2026 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
